Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: results through week 24 from the phase 3 ASTRO study

Ursula Seidler; M Long; Jessica R. Allegretti; Silvio Danese; Matthew Germinaro; Thomas Baker; Yolanda Álvarez; Silke Jörgens; Ling Jiang; H Zhang; Tadakazu Hisamatsu; David T. Rubin; Laurent Peyrin‐Biroulet

doi:10.1055/s-0045-1810725

September 1, 2025Zeitschrift für Gastroenterologie

Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: results through week 24 from the phase 3 ASTRO study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Subcutaneous guselkumab therapy shows notable efficacy in treating ulcerative colitis.
Patients receiving guselkumab reported significant improvements in symptoms over 24 weeks.
The phase 3 ASTRO study assesses the effectiveness of induction therapy for ulcerative colitis.
Findings support subcutaneous administration of IL-23p19 inhibitors to manage ulcerative colitis.

Implication

Phase 3 ASTRO study reveals significant efficacy and safety of guselkumab in ulcerative colitis patients.

Abstract

Introduction: Guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, demonstrated efficacy in patients (pts) with ulcerative colitis (UC) treated with GUS intravenous (IV) induction and subcutaneous (SC) maintenance (QUASAR).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seidler et al. (2025) studied this question.

synapsesocial.com/papers/68c193fb9b7b07f3a06184cf https://doi.org/10.1055/s-0045-1810725

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: results through week 24 from the phase 3 ASTRO study

Key Points

Implication

Abstract

Discussion

Cite This Study

Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: results through week 24 from the phase 3 ASTRO study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading